IRIS
ARDIZZONI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.982
AS - Asia 1.706
EU - Europa 1.261
SA - Sud America 208
AF - Africa 110
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.275
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.931
CN - Cina 574
SG - Singapore 550
FI - Finlandia 268
VN - Vietnam 260
IE - Irlanda 197
SE - Svezia 197
IT - Italia 191
BR - Brasile 155
DE - Germania 140
HK - Hong Kong 108
TR - Turchia 69
FR - Francia 66
ZA - Sudafrica 64
NL - Olanda 48
GB - Regno Unito 47
BD - Bangladesh 33
CA - Canada 31
IN - India 28
UA - Ucraina 28
CI - Costa d'Avorio 26
AR - Argentina 21
PL - Polonia 20
RU - Federazione Russa 13
MX - Messico 12
JP - Giappone 10
PK - Pakistan 10
EC - Ecuador 8
ES - Italia 8
PH - Filippine 8
BE - Belgio 7
MA - Marocco 7
CO - Colombia 6
CZ - Repubblica Ceca 6
IQ - Iraq 6
JO - Giordania 6
LT - Lituania 6
AT - Austria 5
AU - Australia 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
VE - Venezuela 5
CL - Cile 4
ID - Indonesia 4
MY - Malesia 4
PY - Paraguay 4
EG - Egitto 3
KR - Corea 3
NP - Nepal 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
BB - Barbados 2
BY - Bielorussia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
IR - Iran 2
KE - Kenya 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
OM - Oman 2
PE - Perù 2
SI - Slovenia 2
SN - Senegal 2
TH - Thailandia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
TJ - Tagikistan 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.275
Salva come PNG Salva come JPEG
Città #
Singapore 306
Ashburn 271
Chandler 260
Dublin 197
San Jose 148
Beijing 143
Dallas 137
Santa Clara 122
Hong Kong 101
Ho Chi Minh City 82
New York 76
Parma 69
Nanjing 66
Dearborn 62
Johannesburg 60
Izmir 57
Munich 56
Shanghai 54
Boardman 53
Hanoi 53
Los Angeles 44
Ann Arbor 39
Jacksonville 36
Princeton 35
Lauterbourg 33
Abidjan 26
San Mateo 26
Bremen 25
Wilmington 24
Kunming 22
Jinan 20
Turku 20
Helsinki 19
São Paulo 19
Tianjin 18
Shenyang 17
Buffalo 16
Denver 16
Frankfurt am Main 16
Nanchang 15
Hefei 14
Warsaw 14
Da Nang 13
Haiphong 12
Jiaxing 12
Council Bluffs 11
Hebei 11
Seattle 11
Toronto 11
Columbus 10
Marseille 9
Guangzhou 8
Hangzhou 8
London 8
Rio Saliceto 8
Tokyo 8
Brussels 7
Leawood 7
Montreal 7
Phoenix 7
Poplar 7
Zhengzhou 7
Biên Hòa 6
Brooklyn 6
Chennai 6
Haikou 6
Houston 6
Leipzig 6
Norwalk 6
Pune 6
Amman 5
Bexley 5
Chicago 5
Hải Dương 5
Milan 5
Moscow 5
New Delhi 5
Ottawa 5
Rio de Janeiro 5
Rome 5
The Dalles 5
Woodbridge 5
Amsterdam 4
Belo Horizonte 4
Changsha 4
Chengdu 4
City of London 4
Des Moines 4
Fuzhou 4
Istanbul 4
Mexico City 4
Nuremberg 4
Quito 4
San Francisco 4
Stockholm 4
Sydney 4
Taizhou 4
Wroclaw 4
Ankara 3
Bologna 3
Totale 3.247
Salva come PNG Salva come JPEG
Nome #
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 207
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 193
Characterization of gefitinib uptake in NSCLC cell lines 190
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 185
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 180
Histological subtype analysis of colon cancer: a population-based study. Different sides and different diseases. 179
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 177
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 174
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 170
Cancer stem cells related marker CD44 and Notch activation in metastatic colon cancer patients 169
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 168
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 166
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer 166
Neoplasie del polmone in Neoplasie del Distretto Toracico 159
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 158
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 157
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 155
Notch Activation Modulates Bevacizumab Activity by CD44 Positive Cancer Stem Cells in Advanced Colon Cancer 149
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 148
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 146
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 145
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 145
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 139
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 135
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 133
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 131
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
Effect of dual PI3K and FAK inhibition in squamous lung carcinoma with reduced PTEN level 118
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 114
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 111
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 104
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 100
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 90
Totale 5.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.076
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.076
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022120 1 1 1 12 2 0 5 15 9 9 8 57
2022/2023805 70 113 57 63 73 102 5 54 239 0 21 8
2023/2024279 12 21 6 9 24 92 20 18 11 6 14 46
2024/2025953 37 37 51 67 116 92 24 33 144 69 97 186
2025/20261.988 227 175 199 212 308 130 159 78 262 148 62 28
Totale 5.321